Theravance Biopharma

Country

Ownership: -

Employees: 99

Market Cap: -

Website

Introduction: Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Clinical Trials

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TD-1473 for SAD
Drug: Placebo for SAD
Drug: TD-1473 for MAD
Drug: Placebo for MAD

First Posted Date: 2016-01-15

Last Posted Date: 2021-01-19

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 72

Registration Number: NCT02657122

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo Comparator
Drug: TD-0714

First Posted Date: 2015-12-24

Last Posted Date: 2021-10-13

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 56

Registration Number: NCT02639078

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: Placebo
Drug: Velusetrag

First Posted Date: 2014-10-17

Last Posted Date: 2018-04-17

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 233

Registration Number: NCT02267525

TD-6450 MAD Study in HCV Infected Subjects

Phase 1

Completed

Conditions: HCV
Hepatitis C

Interventions: Drug: Placebo
Drug: TD-6450

First Posted Date: 2014-04-17

Last Posted Date: 2021-01-19

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 47

Registration Number: NCT02116543

Locations: 🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

TD-6450 SAD and MAD in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: TD-6450
Drug: Placebo

First Posted Date: 2013-12-27

Last Posted Date: 2021-01-14

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 111

Registration Number: NCT02022306

Locations: 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States

TD-1607 MAD Study in Healthy Subjects

Phase 1

Completed

Conditions: Bacterial Infections
Infections

Interventions: Drug: TD-1607
Drug: Placebo

First Posted Date: 2013-09-24

Last Posted Date: 2021-01-19

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 48

Registration Number: NCT01949103

Locations: 🇺🇸
PPD, Phase 1 Clinic, Austin, Texas, United States

TD-9855 Mass Balance Study

Phase 1

Completed

Conditions: ADHD
Fibromyalgia

Interventions: Drug: TD-9855

First Posted Date: 2013-08-16

Last Posted Date: 2021-01-19

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 6

Registration Number: NCT01924143

TD-1607 SAD Study in Healthy Subjects

Phase 1

Completed

Conditions: Serious Infections Due to Known or Suspected Gram-positive Pathogens

Interventions: Drug: TD-1607
Drug: Placebo

First Posted Date: 2013-02-13

Last Posted Date: 2021-01-19

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 64

Registration Number: NCT01791049

Locations: 🇺🇸
PPD Phase 1, Austin, Texas, United States

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: velusetrag dose 1
Drug: velusetrag dose 2
Drug: velusetrag dose 3
Drug: placebo

First Posted Date: 2012-11-01

Last Posted Date: 2018-02-26

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 34

Registration Number: NCT01718938

Locations: 🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸
GI Associates & Endoscopy Center, Jackson, Mississippi, United States

and more 6 locations

TD-1211 IV/Oral Mass Balance Study

Phase 1

Completed

Conditions: OIC

Interventions: Drug: TD-1211 IV [C14]
Drug: TD-1211 PO [C14]

First Posted Date: 2012-10-05

Last Posted Date: 2021-01-20

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 10

Registration Number: NCT01702194

Locations: 🇺🇸
Covance, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy